Across TCGA pan-cancer cohorts, OR2Z1 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated OR2Z1 data layer compared with 7 for mass-spec protein.
The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher OR2Z1 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated OR2Z1 expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.
SKCM, OV, and UCEC are the cancer types where OR2Z1 Mutation most reproducibly stratifies survival.